44 Cash-Rich Stocks Smart Money Investors Are Buying
Screen Criteria:List of stocks with significant institutional buying, and a significant cash vs operating expense ratio.Average Weekly Returns:Average 1-Week Return of All Stocks...
Symbol | Exchange | Currency |
|---|
Screen Criteria:List of stocks with significant institutional buying, and a significant cash vs operating expense ratio.Average Weekly Returns:Average 1-Week Return of All Stocks...
MAP Pharmaceuticals, Inc. (MAPP), is a development-stage company. As of December 31, 2011, the Company was focusing to advance its product candidate, LEVADEX (MAP0004) orally...
MAP Pharmaceuticals, Inc., a development stage company, focuses on the enhancement of the therapeutic benefits and commercial attractiveness of proven drugs in the field of neurology through its formulation and inhalation technologies. The company’s lead product candidate includes LEVADEX, an orally inhaled version of dihydroergotamine mesylate (DHE) that has completed Phase III clinical trials for the acute treatment of migraine in adults. Its proprietary technologies consist of particle creation and formulation technologies, which can be applied to small or large molecules, including peptides and proteins; and aerosol delivery platforms, such as TEMPO inhaler, a pressurized metered dose inhaler (MDI) that dispenses drug automatically when the patient inhales. MAP Pharmaceuticals, Inc. was founded in 2003 and is based in Mountain View, California. MAP Pharmaceuticals, Inc. operates as a subsidiary of AbbVie Inc.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | |||||
| Technical Indicators | |||||
| Summary |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 207.46 | 207.79 | 197.20 | +12.18 | +6.24% | 168.62M | NASDAQ | |||
| 164.90 | 165.00 | 161.91 | +2.54 | +1.56% | 67.09M | NASDAQ | |||
| 62.03 | 62.25 | 61.87 | +0.18 | +0.29% | 14.06M | NYSE | |||
| 211.94 | 212.17 | 206.77 | +4.10 | +1.97% | 25.22M | NASDAQ | |||
| 103.73 | 103.89 | 101.04 | +2.84 | +2.81% | 35.75M | NASDAQ | |||
| 289.27 | 289.27 | 283.00 | +5.22 | +1.84% | 32.09M | NASDAQ | |||
| 40.80 | 40.83 | 40.28 | +0.42 | +1.04% | 22.83M | NYSE | |||
| 98.01 | 98.36 | 95.27 | +0.13 | +0.13% | 55.43M | NASDAQ | |||
| 103.29 | 103.49 | 101.95 | +1.29 | +1.26% | 55.70M | NASDAQ | |||
| 166.04 | 166.68 | 164.29 | +3.37 | +2.07% | 1.51M | NASDAQ | |||
| 277.77 | 278.34 | 271.05 | +3.94 | +1.44% | 42.98M | NASDAQ | |||
| 8.45 | 8.48 | 8.08 | +0.30 | +3.68% | 26.03M | NYSE | |||
| 104.00 | 104.19 | 101.44 | +2.68 | +2.65% | 27.08M | NASDAQ | |||
| 47.94 | 48.13 | 45.95 | +1.43 | +3.07% | 13.46M | NYSE | |||
| 10.27 | 10.275 | 10.27 | 0.00 | 0.00% | 0.00 | NYSE |